We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Urinary VEGFA and Renal Pathology Evaluated for IgA Nephropathy Patients

By LabMedica International staff writers
Posted on 25 Sep 2021
Print article
The SpectraMax Plus 384 Microplate Reader can run both standard spectrophotometer and microplate reader applications on the same instrument (Photo courtesy of Molecular Devices)
The SpectraMax Plus 384 Microplate Reader can run both standard spectrophotometer and microplate reader applications on the same instrument (Photo courtesy of Molecular Devices)
Immunoglobulin A (IgA) nephropathy (IgAN) is the most common primary glomerulonephritis and is the leading cause of end-stage renal disease (ESRD) in China. Renal biopsy remains the golden standard for diagnosing and monitoring IgA nephropathy (IgAN).

Vascular endothelial growth factor-A (VEGFA) is an essential angiogenic cytokine and found to be crucial for the survival, differentiation and structure maintaining of these glomerular cells. VEGFA is therefore, pivotal for maintaining the glomerular filtration barrier function. The relationship of urinary and renal VEGFA in IgAN patients are still not clear.

Nephrologists at the Sun Yat-sen University (Guangzhou, China) recruited a total of 85 IgAN patients and 71 healthy controls without microscopic hematuria, proteinuria, hepatic disease and with normal serum creatinine. Samples of IgAN patients were obtained at the day of renal biopsy. Serum and morning urine collected from each subject were transferred to a separate vial after centrifuge and stored at −80 ℃ until assayed.

Serum levels of VEGFA were measured by ELH-VEGF-1 ELISA (RayBiotech, Peachtree Corners, GA, USA), and urine VEGFA levels were measured by ELISA from R&D Systems (Minneapolis, MN, USA). Absorbance was measured at 450 nm using the SpectraMax Plus 384 Microplate reader (Molecular Devices, San Jose, CA, USA). Renal biopsies of 27 IgAN patients were randomly selected from enrolled 85 IgAN patients and used for VEGFA testing by immunohistochemistry analysis. The expression levels of VEGFA and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were quantified by real-time PCR using Taqman with a fluorescence detection monitor 7900 Real-time PCR system (Applied Biosystems, Waltham, MA, USA).

The investigators reported that compared with healthy controls, urinary VEGFA level was elevated in IgAN patients (76.19 ± 63.67 pg/mg Cr versus 146.67 ± 232.71 pg/mg Cr), and not correlated with serum VEGFA level. Baseline urinary VEGFA was significantly associated with gender and tubular atrophy/interstitial fibrosis by stepwise multivariate regression analysis. Urinary VEGFA was higher in male patients accompanied with higher serum creatinine, larger proportion of hypertension and recurrent hematuria than in female patients. In the kidney of IgAN patients, VEGFA were robustly expressed in the parietal epithelial cells, podocytes, mesangial cells and tubular epithelial cells. After a follow-up duration of 38.53 ± 27.14 months, IgAN patients with higher urinary VEGFA level were found to have a poorer renal outcome of renal replacement therapy.

The authors concluded that increased urinary VEGFA might reflect certain renal pathology and, although not fully specific, still could be served as a valuable noninvasive indicator in predicting renal progression of IgAN. The study was published on September 8, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:

Sun Yat-sen University 
R&D Systems 
Molecular Devices
Applied Biosystems

Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
Molecular Diagnostic Platform
Silver Supplier
Automated RPR Syphilis Test
Automated RPR Test Kit
Laboratory Automation System
FlexLab Automation

Print article



view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more


view channel

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more


view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more


view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.